endpts.com·Jun 24, 2026
Ionis has received FDA approval for a label expansion of its drug Tryngolza, allowing it to be used for reducing triglycerides and the risk of pancreatitis, significantly enhancing its commercial potential.
Ionis has secured an FDA label expansion for its antisense drug, Tryngolza, to treat triglycerides and pancreatitis, significantly enhancing its commercial potential. This approval highlights an opportunity for investment and partnership in the expanding market for antisense therapies, particularly those targeting lipid disorders.